Anne Chauchereau

List of Publications by Year
in descending order

47 papers	1,746 citations	257450 24 h-index	345221 36 g-index
50 all docs	50 docs citations	50 times ranked	2727 citing authors

#	Article	IF	Citations
1	Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. , 2020, 8, e001535.		11
2	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	7.0	12
3	Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays. SLAS Technology, 2018, 23, 243-251.	1.9	16
4	The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.. Journal of Clinical Oncology, 2017, 35, 5012-5012.	1.6	4
5	A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector. Oncotarget, 2017, 8, 12272-12289.	1.8	9
6	Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer. Oncotarget, 2017, 8, 44654-44668.	1.8	35
7	Abstract 892: ROCK dependent signalling pathways contribution to collective invasion of colorectal carcinoma. , 2017, , .		0
8	Abstract 1138: The protein disulfide isomerase inhibitor XCE853 inhibitsin vitro,ex-vivoandin vivogrowth of human tumors. , 2017, , .		0
9	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Molecular Medicine, 2016, 8, 761-778.	6.9	27
10	Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making. PLoS Genetics, 2016, 12, e1006096.	3.5	24
11	Abstract 3760: XCE853 is a promising protein disulfide isomerase (PDI) inhibitor exhibiting a strong inhibitory activity in preclinical tumor models. , 2016, , .		0
12	Abstract 2995: Loss of SHISA3 is an early event of the epithelial-to-mesenchymal transition associated with chemoresistance in prostate cancer. , 2015, , .		1
13	Abstract 4466: New biomarkers to optimize preclinical development of the PDI inhibitor XCE853. , 2015, , .		0
14	Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells. , 2015, , .		0
15	A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).. Journal of Clinical Oncology, 2014, 32, 5063-5063.	1.6	3
16	Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget, 2014, 5, 667-678.	1.8	34
17	A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. Cancer Research, 2013, 73, 86-96.	0.9	142
18	Abstract 956: Role of the cell cycle regulator LZTS1 in docetaxel resistance of prostate cancer cells and overcoming the docetaxel resistance by cell cycle pharmacological inhibitors.. , 2013, , .		0

#	Article	IF	Citations
19	The IGR-CaP1 Xenograft Model Recapitulates Mixed Osteolytic/Blastic Bone Lesions Observed in Metastatic Prostate Cancer. Neoplasia, 2012, 14, 376-IN1.	5.3	29
20	Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.. Journal of Clinical Oncology, 2012, 30, 213-213.	1.6	32
21	Abstract 823: Integration of microRNA and gene expression signatures from several models of Docetaxel-resistant prostate cancer cell lines. , 2012, , .		0
22	Experimental models for the development of new medical treatments in prostate cancer. European Journal of Cancer, 2011, 47, S200-S214.	2.8	6
23	Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Experimental Cell Research, 2011, 317, 262-275.	2.6	25
24	Ligand-Dependent Degradation of SRC-1 Is Pivotal for Progesterone Receptor Transcriptional Activity. Molecular Endocrinology, 2011, 25, 394-408.	3.7	26
25	A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer, 2011, 105, 847-853.	6.4	369
26	Abstract 1597: A novel preclinical model of prostate cancer bone metastasis derived from a human primary tumor. , 2011, , .		1
27	E2F3 Is a Mediator of DNA Damage-Induced Apoptosis. Molecular and Cellular Biology, 2010, 30, 524-536.	2.3	67
28	Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Annals of Oncology, 2010, 21, 1864-1869.	1.2	40
29	Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. Journal of Drug Targeting, 2010, 18, 812-820.	4.4	43
30	The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. European Journal of Cancer, 2010, 46, 1770-1772.	2.8	83
31	Abstract 4339: Prostate adenocarcinoma and intensive bone remodeling in a new prostate cancer IGR-CaP1 preclinical model derived from a human primary tumor. , 2010, , .		1
32	The quest for the â€˜bony Grailâ€™ of detecting circulating tumour cells in patients with prostate cancer. Annals of Oncology, 2009, 20, 197-199.	1.2	5
33	The postchemotherapy PSA surge syndrome. Annals of Oncology, 2008, 19, 1308-1311.	1.2	60
34	Ligand-Controlled Interaction of Histone Acetyltransferase Binding to ORC-1 (HBO1) with the N-Terminal Transactivating Domain of Progesterone Receptor Induces Steroid Receptor Coactivator 1-Dependent Coactivation of Transcription. Molecular Endocrinology, 2006, 20, 2122-2140.	3.7	57
35	Differential Recruitment of p160 Coactivators by Glucocorticoid Receptor between Schwann Cells and Astrocytes. Molecular Endocrinology, 2006, 20, 254-267.	3.7	42
36	Involvement of Î²-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14260-14265.	7.1	29

#	Article	IF	Citations
37	Effects of FSH and 17Î²-estradiol on the transactivation of estrogen-regulated promoters and cell proliferation in L cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 289-302.	2.5	6
38	Selective Recruitment of p160 Coactivators on Glucocorticoid-Regulated Promoters in Schwann Cells. Molecular Endocrinology, 2004, 18, 2866-2879.	3.7	41
39	HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene, 2004, 23, 8777-8784.	5.9	69
40	Subcellular Localization and Mechanisms of Nucleocytoplasmic Trafficking of Steroid Receptor Coactivator-1. Journal of Biological Chemistry, 2003, 278, 32195-32203.	3.4	45
41	Sumoylation of the Progesterone Receptor and of the Steroid Receptor Coactivator SRC-1. Journal of Biological Chemistry, 2003, 278, 12335-12343.	3.4	125
42	JAB1 Interacts with Both the Progesterone Receptor and SRC-1. Journal of Biological Chemistry, 2000, 275, 8540-8548.	3.4	97
43	Phosphorylation Sites in Ligand-Induced and Ligand-Independent Activation of the Progesterone Receptor. Biochemistry, 1994, 33, 13295-13303.	2.5	26
44	Control of Biosynthesis and Post-Transcriptional Modification of the Progesterone Receptor. Biology of Reproduction, 1992, 46, 174-177.	2.7	50
45	Progress in the study of receptors involved in steroidogenesis and steroid hormone action. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 21-23.	2.5	4
46	Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 239-245.	2.5	38
47	Automation of a chloramphenicol acetyltransferase assay. Analytical Biochemistry, 1990, 188, 310-316.	2.4	10